

**Status as of
May 09, 2025**

Please note

- This is an **early draft of the program which is subject to changes** in both session topics and the schedule. As the content is developed updates will be posted.
- We are excited to celebrate the **10th anniversary** of the EFSPi regulatory statistics meeting this year. To mark this milestone, we have planned a special commemoration on **Day 1** (tentative), which will reflect on the past and look forward to the future of this annual meeting. We will conclude the day with a **get-together featuring the traditional wine tasting**.

10th EFSPi Regulatory Statistics Workshop

10-12 September 2025

Basel Switzerland

Day 1: 10th September 2025, 08:30-17:00 (+2h wine tasting)

Time	Presentation
08:30 – 08:45 (15 min)	Opening Remarks Egbert Biesheuvel (EFSPi President, Viatris, NL)
08:45 – 10:15 (90 min)	“Overture”: Strategic Priorities in Pharmaceutical Statistics Speakers will discuss <ol style="list-style-type: none"> 1. Regulatory priorities in Europe 2. Industry view on regulatory priorities in Europe Followed by a Q&A
10:15 – 10:45 (30 min)	Coffee break
10:45 – 12:30 (105 min)	ICH E20 Guideline on “Adaptive Clinical Trials” – A Critical Discussion from Different Perspectives Homework: To get most out of the session please read the ICH E20 draft guideline on Adaptive Clinical Trials currently on public consultation <i><add link></i> Discussants will pick and discuss one or two topics that they found the most thought-provoking.
12:30 – 14:00 (90 min)	Lunch break and poster session: ESGs and EFSPi Working Groups
14:00 – 15:30 (90 min)	Characterizing the Effect of Treatment Using Hierarchical Composite Endpoints – Risks and Benefits of Win Statistics and Beyond HCEs are proposed in several therapeutic areas with the intent to characterize the effect of treatment by combining different outcomes using Generalized Pairwise Comparisons (e.g. win statistics), Desirability of Outcome Ranking, or Ordinal Longitudinal Models for State Occupancies. Speakers from regulatory agencies as well as industry will critically discuss the need to address a well-defined clinical question of interest, pros and cons of the different approaches, and their role in regulatory decision making.
15:30 – 16:00 (30 min)	Coffee break
16:00 – 17:00 (60 min)	10th Anniversary of the EFSPi Regulatory Statistics Workshop <i>Theme TBC</i>
17:00 – 19:00	Wine tasting organised by Hans Ulrich Burger (Roche, CH) and Emmanuel Zuber (Independent consultant, CH)

Day 2: 11th September 2025, 09:00-17:30

Time	Presentation
09:00 – 11:00 (120 min)	Short Topics: Present a problem on 2-3 slides and receive input from a panel of regulators (20 mins per topic; only F2F presenters allowed) Note: You can submit a problem and, if selected, you can discuss it with a panel of highly esteemed regulators. Proposals should be sent to Vivian Lanius, Vivian.lanius@ucb.com , no later than 11 August 2025.
11:00 – 11:30 (30 min)	Coffee break
11:30 – 12:30 (60 min)	From Black Box to Pandora's Box: Navigating AI in Clinical Trials
12:30 – 14:00 (90 min)	Lunch break
14:00 – 15:30 (90 min)	Keeping it Real or Losing Control? Adventures in Target Trial Emulation Goal: to explore how Target Trial Emulation (TTE) can improve transparency and methodological rigor when designing, evaluating, and assessing clinical trials incorporating observational data. Different stakeholders will gain insights into regulatory expectations, industry experiences, and how TTE enhances alignment and communication between regulators and pharmaceutical companies. This includes how TTE clarifies assumptions, addresses biases, and facilitates robust sensitivity analyses and evaluation criteria through structured links to randomized trials.
15:30 – 16:00 (30 min)	Coffee break
16:00 – 17:30 (90 min)	From Trials to Target Populations: Extending Evidence for Decision-Making [TBC] Speakers will discuss issues of transportability and generalisability

Day 3: 12th September 2025, 09:00-12:10

Time	Presentation
08:30 – 10:00 (90 min)	How to Deal with Assumptions in Drug Development? What Insights Can We Gain from ICH M15?
10:00 – 10:30 (30 min)	Coffee break
10:30 – 12:00 (90 min)	Bayesian Clinical Trial Designs in Drug Development
12:00 – 12:10	Closure